SCHEDULE: Northstrive Fund II LP Exits Enveric Biosciences Stake
Beneficial Ownership Amendment
Braeden Lichti and Northstrive Fund II LP have filed an amendment to their Schedule 13G, indicating they are no longer beneficial owners of Enveric Biosciences, Inc. common stock.
Summary
- Braeden Lichti and Northstrive Fund II LP (the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13G.
- This amendment serves as a final amendment and an exit filing, confirming the Reporting Persons are no longer beneficial owners of any shares of Common Stock of Enveric Biosciences, Inc. (the "Issuer").
- As of December 9, 2025, both Braeden Lichti and Northstrive Fund II LP hold 0% beneficial ownership of the Issuer's common stock.
- The original Schedule 13G was filed on December 5, 2025.
Sentiment
Score: 5
Explanation: Neutral, as this is an administrative filing indicating a change in beneficial ownership, not related to operational performance or strategic developments of the issuer.
Future Outlook
NA
Industry Context
This filing is an administrative disclosure regarding a change in beneficial ownership by an institutional investor and does not provide insights into broader industry trends or Enveric Biosciences' competitive position.
Stakeholder Impact
- Shareholders: Indicates a reduction in institutional ownership by Northstrive Fund II LP and Braeden Lichti to 0%.
Key Dates
| Date | Description |
|---|---|
| 12/05/2025 | Original Schedule 13G filed with the U.S. Securities and Exchange Commission. |
| 12/09/2025 | Date of event which requires filing of this statement; Reporting Persons ceased to be beneficial owners of Enveric Biosciences, Inc. common stock. |
| 12/10/2025 | Date of signature for Amendment No. 1 to Schedule 13G. |
Keywords
Enveric Biosciences, Schedule 13G, Beneficial Ownership, Northstrive Fund II LP, Braeden Lichti, Institutional Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.